PMID- 28188942
OWN - NLM
STAT- MEDLINE
DCOM- 20170404
LR  - 20220321
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 55
IP  - 1
DP  - 2017 Jan
TI  - Photorefractive Keratectomy With Mitomycin-C for High Myopia: Three Year 
      Follow-Up Results.
PG  - 42-48
AB  - Photorefractive keratectomy (PRK) is a safe and effective surgical 
      keratorefractive technique which is done with the application of mitomycin-C 
      (MMC) in cases of high myopia to prevent the formation of corneal haze This study 
      was conducted to evaluate 3-year visual acuity and quality outcomes of PRK-MMC in 
      high myopia. This before-after study was conducted on 20 individuals (40 eyes) 
      with myopia more than 6.0 diopter (D). Visual acuity and quality indices were 
      evaluated before and three years after the procedure and their stability was 
      examined between the 1st and 3rd years. At 3 years after surgery, mean 
      uncorrected visual acuity was 0.03+/-0.06 in the logarithm of minimum angle of 
      resolution (logMAR) unit which showed a significant improvement when compared to 
      baseline (P<0.001) and means best corrected visual acuity was 0.03+/-0.06 logMAR, 
      which showed no significant difference (P=0.730). Manifest refraction spherical 
      equivalent (MRSE) at 3 years (-0.12+/-0.2D) was significantly decreased when 
      compared to baseline (P<0.001), but it did not change significantly after the 1st 
      year and was stable (P=0.368). Mean coma and spherical aberration 3 years 
      postoperatively were -0.54+/-0.26 microm and 0.46+/-0.19 microm, respectively, and neither 
      parameter showed significant differences when compared to baseline (P<0.001). No 
      significant change was found in mesopic contrast sensitivity. The long-term 
      results of this study showed that PRK-MMC could be regarded an effective, safe, 
      and stable procedure in patients with myopia more than 6.0 D.
FAU - Hashemi, Hassan
AU  - Hashemi H
AD  - Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran.
FAU - Salimi, Yahya
AU  - Salimi Y
AD  - Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran. AND 
      Department of Epidemiology and Biostatistics, School of Public Health, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Pir, Poopak
AU  - Pir P
AD  - Noor Research Center for Ophthalmic Epidemiology, Noor Eye Hospital, Tehran, 
      Iran.
FAU - Asgari, Soheila
AU  - Asgari S
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Tehran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
MH  - Adult
MH  - Contrast Sensitivity
MH  - Cornea/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lasers, Excimer/therapeutic use
MH  - Male
MH  - Mitomycin/*administration & dosage
MH  - Myopia/*surgery
MH  - Photorefractive Keratectomy/*methods
MH  - Postoperative Period
MH  - Treatment Outcome
MH  - *Visual Acuity
MH  - Young Adult
OTO - NOTNLM
OT  - Aberration
OT  - High myopia
OT  - Mitomycin C
OT  - Photorefractive keratectomy
OT  - Visual acuity
OT  - Visual quality
EDAT- 2017/02/12 06:00
MHDA- 2017/04/05 06:00
CRDT- 2017/02/12 06:00
PHST- 2017/01/05 00:00 [accepted]
PHST- 2017/02/12 06:00 [entrez]
PHST- 2017/02/12 06:00 [pubmed]
PHST- 2017/04/05 06:00 [medline]
PST - ppublish
SO  - Acta Med Iran. 2017 Jan;55(1):42-48.